ReviewCurrent cancer drug targets2026
Artificial Intelligence (AI) and Liquid Biopsy Transforming Early Detection of Liver Metastases in Gastrointestinal Cancers.
Review in Current cancer drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Research trends and hotspots of circulating tumor DNA in colorectal cancer: a bibliometric study.Frontiers in oncology · 2025Pooled it
- Artificial intelligence-powered liquid biopsy in cancer: a paradigm shift in cancer detection and personalized care.Cancer cell international · 2026Review
- Recapitulating lung cancer metastasisOncology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver metastases from Gastrointestinal (GI) cancers present significant challenges in oncology, often signaling poor prognosis. Traditional detection methods like imaging and tissue biopsies have limitations in sensitivity, specificity, and tumor heterogeneity representation. The advent of artificial intelligence (AI) in healthcare, driven by advancements in machine learning, algorithms, and data science, offers a promising frontier for early detection and management of liver metastases. This review explores the integration of AI and liquid biopsy technologies as transformative tools in the proactive detection of liver metastases arising from GI malignancies. Liquid biopsy, a non-invasive method, analyzes circulating tumor cells (CTCs), cell-free DNA (cfDNA), and circulating tumor DNA (ctDNA) in bodily fluids. It provides a comprehensive overview of tumor heterogeneity and enables real-time monitoring of tumor evolution and treatment response. Despite its advantages, liquid biopsy faces challenges such as low sensitivity for early-stage metastases, reduced detectability due to liver filtration, and technical limitations. AI enhances the potential of liquid biopsies by improving diagnostic accuracy through advanced algorithms like Convolutional Neural Networks (CNNs) and Natural Language Processing (NLP). These AI models analyze complex biomedical data, offering higher sensitivity and specificity in cancer detection. The synergy between AI and liquid biopsies promises early detection, better disease monitoring, and personalized treatment strategies. This review underscores the significant advancements AI and liquid biopsy technologies bring to oncological precision medicine, particularly in improving overall survival (OS) and disease-free survival (DFS) for patients with GI cancer metastases. As we transition into the era of precision medicine, the integration of these technologies holds the potential to redefine cancer care and patient management.
Indexed as
Identifiers
39844562What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.